Bone morphogenetic protein receptor type II and inflammation are bringing old concepts into the new pulmonary arterial hypertension world

American Journal of Respiratory and Critical Care Medicine

Volumn 192, Issue 7, 2015, Pages 777-779

  Perros, Frédéric ^a,b,c   Bonnet, Sébastien ^c  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

^c LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN RECEPTOR 2; EXTRACELLULAR SUPEROXIDE DISMUTASE; GAMMA INTERFERON; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; MICRORNA; STAT3 PROTEIN; TEMPOL; TOLL LIKE RECEPTOR 4; TRICHOSTATIN A; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE;

ARTERIAL WALL THICKNESS; AUTOIMMUNITY; DERMATOPHAGOIDES; DNA DAMAGE; DNA MODIFICATION; DOWN REGULATION; EDITORIAL; ENDOTHELIAL DYSFUNCTION; EPIGENETICS; HISTONE METHYLATION; HUMAN; INFLAMMATION; LOSS OF FUNCTION MUTATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN PHOSPHORYLATION; PULMONARY ARTERY SMOOTH MUSCLE CELL; PULMONARY HYPERTENSION; SIGNAL TRANSDUCTION; SYSTOLIC BLOOD PRESSURE; TH17 CELL; TH2 CELL; UPREGULATION; VASCULAR REMODELING; ANIMAL; BIOSYNTHESIS; DEFICIENCY; PATHOPHYSIOLOGY;

ANIMALS; BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE II; CYTOKINES; HUMANS; HYPERTENSION, PULMONARY;

EID: 84943257033     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201506-1115ED     Document Type: Editorial

References (16)

1. Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, Gomez Sanchez MA, Krishna Kumar R, Landzberg M, Machado RF, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013;62(25 Suppl):D34-D41.
2. Ranchoux B, Antigny F, Rucker-Martin C, Hautefort A, Péchoux C, Bogaard HJ, Dorfmüller P, Remy S, Lecerf F, Planté S, et al. Endothelial-to-mesenchymal transition in pulmonary hypertension. Circulation 2015;131:1006-1018.
3. Machado RD, Eickelberg O, Elliott CG, Geraci MW, Hanaoka M, Loyd JE, Newman JH, Phillips JA III, Soubrier F, Trembath RC, et al. Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol 2009;54(1 Suppl):S32-S42.
4. Cohen-Kaminsky S, Hautefort A, Price L, Humbert M, Perros F. Inflammation in pulmonary hypertension: what we know and what we could logically and safely target first. Drug Discov Today 2014;19: 1251-1256.
5. Hagen M, Fagan K, Steudel W, Carr M, Lane K, Rodman DM, West J. Interaction of interleukin-6 and the BMP pathway in pulmonary smooth muscle. Am J Physiol Lung Cell Mol Physiol 2007;292: L1473-L1479.
6. Soon E, Crosby A, Southwood M, Yang P, Tajsic T, Toshner M, Appleby S, Shanahan CM, Bloch KD, Pepke-Zaba J, et al. Bone morphogenetic protein receptor type II deficiency and increased inflammatory cytokine production: a gateway to pulmonary arterial hypertension. Am J Respir Crit Care Med 2015;192: 859-872.
7. Paulin R, Meloche J, Bonnet S. STAT3 signaling in pulmonary arterial hypertension. JAK-STAT 2012;1:223-233.
8. Meloche J, Pflieger A, Vaillancourt M, Paulin R, Potus F, Zervopoulos S, Graydon C, Courboulin A, Breuils-Bonnet S, Tremblay E, et al. Role for DNA damage signaling in pulmonary arterial hypertension. Circulation 2014;129:786-797.
9. Li M, Vattulainen S, Aho J, Orcholski M, Rojas V, Yuan K, Helenius M, Taimen P, Myllykangas S, De Jesus Perez V, et al. Loss of bone morphogenetic protein receptor 2 is associated with abnormal DNA repair in pulmonary arterial hypertension. Am J Respir Cell Mol Biol 2014;50:1118-1128.
10. Meloche J, Pflieger A, Vaillancourt M, Graydon C, Provencher S, Bonnet S. miRNAs in PAH: biomarker, therapeutic target or both? Drug Discov Today 2014;19:1264-1269.
11. Archer SL, Marsboom G, Kim GH, Zhang HJ, Toth PT, Svensson EC, Dyck JRB, Gomberg-Maitland M, Thébaud B, Husain AN, et al. Epigenetic attenuation of mitochondrial superoxide dismutase 2 in pulmonary arterial hypertension: a basis for excessive cell proliferation and a new therapeutic target. Circulation 2010;121: 2661-2671.
12. Brock M, Samillan VJ, Trenkmann M, Schwarzwald C, Ulrich S, Gay RE, Gassmann M, Ostergaard L, Gay S, Speich R, et al. AntagomiR directed against miR-20a restores functional BMPR2 signalling and prevents vascular remodelling in hypoxia-induced pulmonary hypertension. Eur Heart J 2014;35:3203-3211.
13. Bauer EM, Shapiro R, Zheng H, Ahmad F, Ishizawar D, Comhair SA, Erzurum SC, Billiar TR, Bauer PM. High mobility group box 1 contributes to the pathogenesis of experimental pulmonary hypertension via activation of Toll-like receptor 4. Mol Med 2012;18: 1509-1518.
14. Mushaben EM, Hershey GK, Pauciulo MW, Nichols WC, Le Cras TD. Chronic allergic inflammation causes vascular remodeling and pulmonary hypertension in BMPR2 hypomorph and wild-type mice. PLoS One 2012;7:e32468.
15. Hautefort A, Girerd B, Montani D, Cohen-Kaminsky S, Price L, Lambrecht BN, Humbert M, Perros F. T-helper 17 cell polarization in pulmonary arterial hypertension. Chest 2015;147:1610-1620.
16. Summers SA, Odobasic D, Khouri MB, Steinmetz OM, Yang Y, Holdsworth SR, Kitching AR. Endogenous interleukin (IL)-17A promotes pristane-induced systemic autoimmunity and lupus nephritis induced by pristane. Clin Exp Immunol 2014;176:341-350.